GoodRx Holdings Chief Accounting Officer Resigns
In a regulatory filing, the company stated, "On March 24, 2026, Romin Nabiey submitted his resignation as Chief Accounting Officer of GoodRx Holdings, effective April 3, 2026 in order to pursue other opportunities. Nabiey will remain an employee of the company through June 8, 2026 to support the transition of his responsibilities. Nabiey's resignation was not a result of any disagreement between the company and Nabiey on any matter related to the operations, policies, or practices of the company."
Trade with 70% Backtested Accuracy
Analyst Views on GDRX
About GDRX
About the author
GoodRx Partners with Viatris to Offer Up to 85% Discounts on Medications
- Discount Program Launch: GoodRx has partnered with Viatris to introduce a new program offering up to 85% discounts on 17 brand-name medications, including the cholesterol drug Lipitor, which is expected to significantly reduce patient medication costs.
- Extensive Coverage: The discount program will be available at over 70,000 pharmacies across the U.S., making it easier for patients to access necessary medications, thereby enhancing GoodRx's market position in drug price transparency and accessibility.
- Insurance Patient Benefits: Some Viatris medications will be available on GoodRx for as low as $0–$4 for patients with commercial insurance, a strategy that not only expands GoodRx's user base but may also improve patient adherence to medication regimens.
- Market Response: GoodRx noted that the selected medications already generate significant search volume on its platform, indicating strong market demand for these drugs, which further solidifies GoodRx's influence in the healthcare sector.
GOODRX TEAMS UP WITH VIATRIS TO PROVIDE UP TO 85% DISCOUNTS ON WELL-KNOWN BRAND MEDICATIONS
Partnership Announcement: GoodRx has partnered with Viatris to provide significant savings on established brand medications.
Savings Details: The collaboration offers up to 85% savings for consumers on select medications through GoodRx's platform.
GoodRx Partners with Eli Lilly to Lower Medication Costs
- Employer Funding Model: GoodRx Employer Direct enables self-insured employers to subsidize the $449 price of Eli Lilly's Zepbound KwikPen, significantly reducing employee out-of-pocket costs and enhancing access to obesity management medications.
- Real-Time Integration Mechanism: GoodRx integrates manufacturer discounted pricing with employer funding in real time, ensuring that employer contributions are seamlessly applied to medication costs, creating a more transparent payment pathway and enhancing employer sustainability.
- Simplified Access Process: This model does not alter employers' core health benefit structures, allowing them to flexibly control subsidy amounts while offering a direct-to-consumer telemedicine solution that simplifies the GLP-1 treatment journey.
- Market Demand Response: As demand for GLP-1 obesity treatment rises, the collaboration between GoodRx and Eli Lilly demonstrates how to meet employer needs through transparent solutions, further expanding access to obesity management medications.
GoodRx Holdings Inc. Enables Self-Insured Employers to Offset $449 Lilly Price for Zebound KwikPen Through GoodRx
Company Overview: GoodRx Holdings is a company that operates in the healthcare sector, focusing on providing prescription drug pricing information and discounts to consumers.
Financial Insights: The company has a market capitalization of approximately $449 million, indicating its valuation in the stock market.
Product Offering: GoodRx offers a service that allows users to compare prices for medications, helping them find the best deals available.
Recent Developments: The company has been involved in discussions regarding potential subsidies for self-insured employers, which could impact its business model and revenue streams.
GoodRx Holdings Inc. Partners with Eli Lilly to Enhance Employer Access to Zepbound KwikPen
Partnership Announcement: GoodRx Holdings has partnered with Eli Lilly to enhance employer access to Zepbound, a medication for weight management.
Focus on Accessibility: The collaboration aims to improve the availability of Zepbound for employers, potentially increasing patient access to the treatment.
GOODRX TO BROADEN EMPLOYER-SPONSORED AVAILABILITY OF ZEPBOUND® KWIKPEN®
- Employer-Sponsored Access: GoodRx is expanding its employer-sponsored access program to include Zepbound® and KwikPen® products.
- Focus on Accessibility: The initiative aims to improve accessibility to these medications for employees through their employers.
GoodRx Partners with Viatris to Offer Up to 85% Discounts on Medications
- Discount Program Launch: GoodRx has partnered with Viatris to introduce a new program offering up to 85% discounts on 17 brand-name medications, including the cholesterol drug Lipitor, which is expected to significantly reduce patient medication costs.
- Extensive Coverage: The discount program will be available at over 70,000 pharmacies across the U.S., making it easier for patients to access necessary medications, thereby enhancing GoodRx's market position in drug price transparency and accessibility.
- Insurance Patient Benefits: Some Viatris medications will be available on GoodRx for as low as $0–$4 for patients with commercial insurance, a strategy that not only expands GoodRx's user base but may also improve patient adherence to medication regimens.
- Market Response: GoodRx noted that the selected medications already generate significant search volume on its platform, indicating strong market demand for these drugs, which further solidifies GoodRx's influence in the healthcare sector.
GOODRX TEAMS UP WITH VIATRIS TO PROVIDE UP TO 85% DISCOUNTS ON WELL-KNOWN BRAND MEDICATIONS
Partnership Announcement: GoodRx has partnered with Viatris to provide significant savings on established brand medications.
Savings Details: The collaboration offers up to 85% savings for consumers on select medications through GoodRx's platform.
GoodRx Partners with Eli Lilly to Lower Medication Costs
- Employer Funding Model: GoodRx Employer Direct enables self-insured employers to subsidize the $449 price of Eli Lilly's Zepbound KwikPen, significantly reducing employee out-of-pocket costs and enhancing access to obesity management medications.
- Real-Time Integration Mechanism: GoodRx integrates manufacturer discounted pricing with employer funding in real time, ensuring that employer contributions are seamlessly applied to medication costs, creating a more transparent payment pathway and enhancing employer sustainability.
- Simplified Access Process: This model does not alter employers' core health benefit structures, allowing them to flexibly control subsidy amounts while offering a direct-to-consumer telemedicine solution that simplifies the GLP-1 treatment journey.
- Market Demand Response: As demand for GLP-1 obesity treatment rises, the collaboration between GoodRx and Eli Lilly demonstrates how to meet employer needs through transparent solutions, further expanding access to obesity management medications.
GoodRx Holdings Inc. Enables Self-Insured Employers to Offset $449 Lilly Price for Zebound KwikPen Through GoodRx
Company Overview: GoodRx Holdings is a company that operates in the healthcare sector, focusing on providing prescription drug pricing information and discounts to consumers.
Financial Insights: The company has a market capitalization of approximately $449 million, indicating its valuation in the stock market.
Product Offering: GoodRx offers a service that allows users to compare prices for medications, helping them find the best deals available.
Recent Developments: The company has been involved in discussions regarding potential subsidies for self-insured employers, which could impact its business model and revenue streams.
GoodRx Holdings Inc. Partners with Eli Lilly to Enhance Employer Access to Zepbound KwikPen
Partnership Announcement: GoodRx Holdings has partnered with Eli Lilly to enhance employer access to Zepbound, a medication for weight management.
Focus on Accessibility: The collaboration aims to improve the availability of Zepbound for employers, potentially increasing patient access to the treatment.
GOODRX TO BROADEN EMPLOYER-SPONSORED AVAILABILITY OF ZEPBOUND® KWIKPEN®
- Employer-Sponsored Access: GoodRx is expanding its employer-sponsored access program to include Zepbound® and KwikPen® products.
- Focus on Accessibility: The initiative aims to improve accessibility to these medications for employees through their employers.
